Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Clin Cancer Res. 2022 Nov 1;28(21):4669–4676. doi: 10.1158/1078-0432.CCR-22-1113

Table 1.

Patient and tumor characteristics

Patient and Tumor Characteristics Training Set Testing Set
Cases BPM† P-value‡ Cases BPM† P-value‡
Number of Subjects, N 101 134 118 56
Age, average (min-max) 59 (23–85) 57 (30–83) 0.14 61 (36–86) 55 (33–79) 0.009
Menopausal Status, N (%)
Pre 21 (20.8%) 39 (29.1%) 0.17 19 (16.1%) 18 (32.1%) 0.02
Post 80 (79.2%) 95 (70.9%) 99 (83.8%) 38 (67.8%)
Race, N (%)
White 83 (82.2%) 104 (77.6%) 0.18 87 (73.7%) 42 (75%) 0.52
Black 5 (5%) 3 (2.2%) 9 (7.6%) 9 (16.1%)
Asian 2 (2%) 3 (2.2%) 13 (11%) 1 (1.8%)
American Indian - 1 (0.7%) - -
Pacific Islander - - 9 (7.6%) 4 (7.1%)
Unknown 11 (10.9%) 23 (17.2%) - -
Stage, N (%)
Stage I and II 39 (38.6%) - 20 (16.9%) -
Stage III and IV 62 (61.4%) - 98 (83.1%) -
Histological Subtype, N (%)
Serous 69 (68.3%) - 114 (96.6%) -
Non-Serous 32 (31.7%) - 1 (0.8%) -
Unknown 3 (2.54%)
ROMA, median (25th/75th Percentiles) 86.85 (36.85–98.03) 11.14 (6.64–20.66) <0.0001 89.51 (70.55–96.95) 13.66 (6.42–18.56) <0.0001
†

individuals with benign pelvic masses (BPM)

‡

Statistical significance was determined by Wilcoxon rank sum tests for continuous variables and Fisher’s exact test or χ2 tests for trend for categorical variables. 2-sided p-values are reported.